November 2026

Black Hawk

Completed its Business Combination with

Vesicor Therapeutics

$70,000,000

Capital Markets Advisor

D. BORAL CAPITAL

For more information please contact:

Investment Banking

Stephanie Hu
Co-Head of Investment Banking
Direct: +1 (929) 586-0272
shu@dboralcapital.com

Patrick Lin
Associate
Direct: +1 (929) 615-2558
plin@dboralcapital.com

Equity Capital Markets

Philip Wiederlight
Chief Operating Officer
Direct: +1 (929) 625-1539
pwiederlight@dboralcapital.com

Mark Iorio
Head of Equity Capital Markets
Direct: +1 (929) 528-0913
miorio@dboralcapital.com

D. Boral Capital Served as Capital Markets Advisor for Black Hawk Acquisition Corporation which has completed its Business Combination with Vesicor Therapeutics

Transaction Information

On November 20, 2026, Vesicor Therapeutics Holdings, Inc. ("Vesicor" or the "Company"), an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles, announced the closing of its previously announced business combination with Black Hawk Acquisition Corporation (Nasdaq: BKHA) ("Black Hawk"). The transaction was approved by Black Hawk's shareholders at an extraordinary general meeting held on October 13, 2026 and closed on November 19, 2026. In connection with the closing, Black Hawk domesticated from the Cayman Islands to Delaware and changed its name to Vesicor Therapeutics Holdings, Inc. The Company's common stock is expected to begin trading on the Nasdaq Capital Market under the ticker symbol "VESI" on November 23, 2026.

D. Boral Capital LLC served as Capital Markets Advisor to Black Hawk Acquisition Corporation for the Business Combination and as Underwriter for the SPAC IPO.

About Vesicor Therapeutics

Vesicor Therapeutics Holdings, Inc. is an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles. The Company's product candidate, ecm-RV/p53, is being advanced toward IND-enabling studies and an Investigational New Drug application with the U.S. Food and Drug Administration. Founded in 2008, Vesicor is headquartered in San Gabriel, California. For more information, visit [www.vesicor.com].

About Black Hawk Acquisition Corporation

Black Hawk Acquisition Corporation was a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Black Hawk completed its initial public offering in March 2024 and its ordinary shares, rights and units were listed on Nasdaq under the symbols "BKHA," "BKHAR" and "BKHAU."

About D. Boral Capital

D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.

A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately $40 billion in capital since its inception in 2020, executing ~400 transactions across a broad range of investment banking products.

D. Boral Capital is a member of FINRA and SIPC.